Trial Profile
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Bradykinin (Primary) ; Nesiritide (Primary) ; Sacubitril/valsartan (Primary) ; Sitagliptin (Primary) ; Substance P (Primary) ; Valsartan (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics
- Acronyms Aim 1
- 01 Mar 2024 Planned End Date changed from 31 Dec 2021 to 31 Dec 2025.
- 01 Mar 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
- 25 Apr 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2024.